FathomX

Value Proposition: 1. Achieve better accuracy (AUC): FxMammo AI model has achieved an AUC of 0.943— demonstrating robust performance in clinical settings. The model is clinically validated in multi-country multi-centre, achieved average AUC 0.902, highest at AUC 0.943. 2.Dense breast advantage: Asian populations where breast density is significantly higher. Competing AIs were primarily trained on western data, our AI includes training & validating on Asian data, it can optimize the performance where standard models often underperform; 3. Offline-Ready AI Deployment Model: We can achieve a seamless integration, alternatively, we can also deploy the solution offline-ready. This helps clinicians to gain confidence in the software’s security concerns. Most cloud-native competitors require always-on internet access — FathomX’s edge-first model will become a market wedge. 4. Team Expertise: Our company is a spin-off from the National University of Singapore, our team brings together deep academic rigor and industry-savvy execution. Comprising domain experts, seasoned researchers, and product engineers, we are uniquely positioned to deliver high-quality, research-driven solutions with real-world impact. 5. Device-agnostic & Flexible Cost: Our AI works across different hardware and imaging systems—regardless of vendor or manufacturer. FathomX supports vendor-neutral DICOM formats, working seamlessly with GE, Siemens, Fujifilm, Philips, etc. — huge cost and flexibility win for mid-tier hospitals. 6. Deep Institutional Relationships: FathomX has continuous relationships with institutions enabling diverse datasets and performance in local regions. This bridges the gap between academic rigor and clinical applicability, giving it a strong differentiator against purely commercial competitors. Competitor AIs prioritize commercial deployment, with fewer visible peer-reviewed research collaborations.